Breaking News

AMRI Completes Cedarburg Acquisition

April 7, 2014

Expands resources for complex drug development services and products

AMRI has completed the acquisition of Cedarburg Pharmaceuticals, Inc. for a total consideration of $41 million, including assumption of certain liabilities.
 
The acquisition of Cedarburg, a contract developer and manufacturer of technically complex API's for both generic and branded drug products, is part of AMRI's strategy to expand its presence as a supplier of custom and complex drug development services and product. Customers will now have access to expanded resources, including development of complex API, expanded scale-up capabilities and large-scale manufacturing.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016